Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus Optimized Background Therapy in the MOTIVATE 1 and 2 Trials

REFERENCES

• Di Giambenedetto S, Colafigli M, Pinnetti C, et al. Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. AIDS Res Hum Retroviruses. 2008;24:149–154.
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Garrido C, Corral A, et al. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retrovi-ruses. 2007;23:879–885.
   PubMed Web of Science ®Google Scholar
• Zaccarelli M, Lorenzini P, Checcherini-Silberstein F, et al. Historical resistance profile helps to predict salvage failure. Antivir Ther. 2009;14:285–291.
   PubMed Web of Science ®Google Scholar
• Cheung PK, Wynhoven B, Harrigan PR. 2004: which HIV-1 drug resistance mutations are common in clinical prac-tice? AIDS Rev. 2009;6: 107–116.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Viard JP, et al. Time to viro-logical failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004;190:1947–1956.
   PubMed Web of Science ®Google Scholar
• Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393–1401.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Dunn D, Sabin C, et al. Long term prob-ability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 2005;19:487–494.
   PubMed Web of Science ®Google Scholar
• Zaccarelli M, Tozzi V, Lorenzini P, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS. 2005;19:1081–1089.
   PubMed Web of Science ®Google Scholar
• Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65–71.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009. Available at: http://aidsinfo.nih.gov/Guidelines/Default.aspx?Menultem=Guidelines. Accessed May 7, 2010.
   Google Scholar
• Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857): a potent, orally bioavailable and selective small-molecule inhibitor of the chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49: 4721–4732.
   PubMed Web of Science ®Google Scholar
• Hardy WD, Gulick R, Mayer H, et al. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies. Presented at: Ninth International Congress on Drug Therapy in HIV Infection; Glasgow, UK. Abstract 0425.
   Google Scholar
• Gulick R, Lalezari J, Goodrich J, et al. for the MOTI-VATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359: 1429–1441.
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Nelson M, Lazzarin A, et al. for the MOTI-VATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442–1455.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359:355–365.
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–1178.
   PubMed Web of Science ®Google Scholar
• Valdez H, Lewis M, Delogne C, et al. Weighted OBT sus-ceptibility score (wOBTSS) is a stronger predictor of viro-logic response at 48 weeks than baseline tropism result in MOTIVATE 1 and 2. Presented at: 48th Interscience Con-ference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; October 25–28, 2008; Washington, DC, USA. Poster H–1221.
   Google Scholar
• Boucher C, Schapiro JM, Llibre JM, et al. A Genotypic weighted OBT susceptibility score (g-wOBTSS) is a predic-tor of virological response <50 copies/mL at 48 weeks in MOTIVATE 1 and 2. Presented at: 7th European HIV Drug Resistance Workshop; Sweden, Stockholm. Abstract 112.
   Google Scholar
• Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194:926–930.
   PubMed Web of Science ®Google Scholar
• Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol. 2003;77:7682–7688.
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Goodrich J, Cooper DA, et al. CD4+T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2 [published online ahead of print 2009]. J Acquir Immune Defic Syndr. doi: 10.1097/QA1.0b013e3181caebaa.
   Web of Science ®Google Scholar
• Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566–575.
   PubMed Web of Science ®Google Scholar
• Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593–1601.
   PubMed Web of Science ®Google Scholar
• Monforte A, Abrams D, Pradier C, et al. HIV-induced immu-nodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22: 2143–2153.
   PubMed Web of Science ®Google Scholar
• Baker JV, Peng G, Rapkin J, et al. CD4+count and risk of non-AIDS diseases following initial treatment for HIV infec-tion. AIDS. 2008;22:841–848.
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Kreuzberg C, Ander Heiden M, Kollan C, Hamouda O, van Lunzen J. Risk of new AIDS-defining events in patients with advanced immunodeficiency dur-ing suppressive HAART: results from the German ClinSury cohort. Presented at: 9th International Congress on Drug Therapy in HIV Infection; Glasgow, UK. Abstract 0423.
   Google Scholar
• Reekie J, Mocroft A, Engsig F, et al. Relationship between current level of immunodeficiency and non-AIDS defining malignancies. Presented at: 16th Conference on Retro-viruses and Opportunistic Infections; Montreal, Canada. Abstract 860a.
   Google Scholar
• Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72–77.
   PubMed Web of Science ®Google Scholar
• Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients dur-ing the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49:1109–1116.
   PubMed Web of Science ®Google Scholar
• Neaton JD, Lane HC. Getting personal about treating HIV. Nat Med. 2008;14:369–370.
   PubMed Web of Science ®Google Scholar
• LaBonte JA, Madani N, Sodroski J. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression. J Virol. 2003;77:6645–6659.
   PubMed Web of Science ®Google Scholar
• Lelievre JD, Petit F, Perrin L, et al. The density of core-ceptors at the surface of CD4+T cells contributes to the extent of human immunodeficiency virus type 1 viral repli-cation-mediated T cell death. AIDS Res Hum Retroviruses. 2004;20:1230–1243.
   PubMed Web of Science ®Google Scholar
• Ahuja SK, Kulkarni H, Catano G, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008;14:413–420.
   PubMed Web of Science ®Google Scholar
• Decrion AZ, Dichampl, Varin A, Herbein G. HIV and inflam-mation. Curr HIV Res. 2005;3:243–259.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+T cell gains in human immu-nodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–1543.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Battegay M, Cooper DA, et al. CD4 + Cell increases at 48 weeks in the maraviroc treatment-naive MERIT trial. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meet-ing of the Infectious Diseases Society of America; October 26–28, 2008; Washington, DC, USA. Poster H–1248.
   Google Scholar